Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03226899 · ClinicalTrials.gov registry record · Phase 4
A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment
A Phase 4 study, sponsored by Ironwood Pharmaceuticals.
- Terminated
- Registry status
- Phase 4
- Development phase
- 242
- Enrollment target
NCT03226899 is a Phase 4 study that was terminated before completion, run by Ironwood Pharmaceuticals. The registered enrollment target is 242 participants.
The verdict
NCT03226899, a Phase 4 study, was terminated before completion, sponsored by Ironwood Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 242 participants
- Enrollment target
Study Summary
This study evaluates the safety and efficacy of lesinurad administered with an XOI versus a placebo plus an XOI in gout participants who have moderate renal impairment and who are not at target level of serum urate (sUA).
Interventions
- DRUG Placebo
- DRUG Lesinurad
- DRUG corticosteroids
- DRUG colchicine
- DRUG XOI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2017-07-19 |
| Est. Completion | 2019-02-25 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03226899
The ClinicalTrials.gov registry entry for NCT03226899 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 242 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ironwood Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT03226899 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03226899 about?
NCT03226899 is a clinical study titled "A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment". This study evaluates the safety and efficacy of lesinurad administered with an XOI versus a placebo plus an XOI in gout participants who have moderate renal impairment and who are not at target level of serum urate (sUA).
What is the current status of trial NCT03226899?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 242 participants. The study started on 2017-07-19. Estimated completion is 2019-02-25.
What interventions are being tested in trial NCT03226899?
The interventions under investigation include: Placebo (DRUG), Lesinurad (DRUG), corticosteroids (DRUG), colchicine (DRUG), XOI (DRUG).
Who is sponsoring clinical trial NCT03226899?
This trial is sponsored by Ironwood Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.